NASDAQ:RXII RXi Pharmaceuticals (RXII) Stock Price, News & Analysis → 55x Gains Instead of 9x Gains (From Weiss Ratings) (Ad) Free RXII Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.78▼$0.8350-Day Range$0.36▼$0.5052-Week Range$0.31▼$7.70Volume137,812 shsAverage Volume1.73 million shsMarket Capitalization$3.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get RXi Pharmaceuticals alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About RXi Pharmaceuticals Stock (NASDAQ:RXII)Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.Read More Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. RXII Stock News HeadlinesOctober 26, 2023 | finance.yahoo.comRex International Holding Ltd (RXI.SG)April 19, 2023 | thestreet.comGalena's Breast Cancer Vaccine Doomed to FailMay 5, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 20, 2023 | finance.yahoo.comQ4 2022 Catalyst Pharmaceuticals Inc Earnings CallSeptember 30, 2022 | finance.yahoo.comiShares Global Consumer Discretionary ETF (RXI)See More Headlines Receive RXII Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2018Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RXII CUSIPN/A CIK1533040 Webwww.rxipharma.com Phone(508) 767-3861FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,450,000.00 Net Margins-4,990.20% Pretax MarginN/A Return on Equity-412.15% Return on Assets-179.54% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual Sales$10,000.00 Price / Sales359.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.06Miscellaneous Outstanding Shares4,380,000Free FloatN/AMarket Cap$3.59 million OptionableNot Optionable Beta2.07 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesGerrit DispersynPresident, Chief Executive Officer & DirectorJames CardiaVice President-Business OperationsCaitlin KontulisSecretary, VP-Finance & AdministrationSimon FrickerVice President-ResearchKey CompetitorsAgile TherapeuticsNASDAQ:AGRXAvenue TherapeuticsNASDAQ:ATXIAraviveNASDAQ:ARAVVirpax PharmaceuticalsNASDAQ:VRPXNovaBay PharmaceuticalsNYSE:NBYView All Competitors RXII Stock Analysis - Frequently Asked Questions How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%. When did RXi Pharmaceuticals' stock split? RXi Pharmaceuticals's stock reverse split on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and This page (NASDAQ:RXII) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
